ELV · Elevance Health, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ELV
this stock
Elevance Health, Inc.
|
$85.90B | +12.0% | +12.5% | 17.5 | 2.5% |
|
UNH
Unitedhealth Group Inc
|
$338.03B | +13.6% | +11.8% | — | 1.5% |
|
CVS
CVS HEALTH Corp
|
$110.82B | +9.8% | +7.8% | 22.9 | 1.3% |
|
CI
Cigna Group
|
$71.06B | +0.0% | +11.2% | 11.1 | 2.5% |
|
HUM
Humana Inc
|
$47.78B | +51.0% | +10.1% | 42.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ELV | -2.4% | +0.1% | +23.4% | +0.1% | +12.0% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | -1.2% | +0.4% | +10.4% | +0.4% | 0.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.